Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Prommis Trial Prospectively Demonstrates the Efficacy of SKY92 Risk Stratification in Newly Diagnosed Multiple Myeloma Patients

Noa Biran, Binod Dhakal, Ruben Niesvizky, Suzanne Lentzsch, John T. McKay, David H. Vesole, Ajay K. Nooka, Barry Paul, Parameswaran N. Hari, Lisette Stork-Sloots, Silvia D'Ambrosi, Rowan Kuiper, Martin van Vliet, David S. Siegel, Saad Z Usmani, Frits van Rhee

Blood (2023) 142 (Supplement 1): 3386.

https://doi.org/10.1182/blood-2023-180761

Published: 2023

Journal Articles

Unveiling the Discrepancy in Multiple Myeloma Risk Classification between Clinical Practice and SKY92 Test and the Impact on Survival

Blood (2023) 142 (Supplement 1): 2013.

https://doi.org/10.1182/blood-2023-181905

Published: 2023

Journal Articles

Combining Plasma Cell Leukemia-like Status with the Second Revision of the International Staging System Improves Risk Classification

Blood (2022) 140 (Supplement 1): 1566–1567.

https://doi.org/10.1182/blood-2022-170249

Published: 2022

Journal Articles

High-Risk Multiple Myeloma Patients Are Missed without Gene Expression Profiling

Martin H Van Vliet, Yan-Ting Chen, PhD, Erik H Van Beers, PhD, Rowan Kuiper, PhD, Erik T. Valent, PhD, Marieke Spaan, MSc, Carolina Terragna, Elena Zamagni, Michele Cavo, Stefania Oliva, Alessandra Larocca, Torsten Haferlach, MD, Wee-Joo Chng, MBBS, PhD FRCPath, FRCP, Anders Waage, MD PhD, M Duin, Pieter Sonneveld, MD PhD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-137389

Published: 2020

Journal Articles

The Prognostic Power of Gene Expression Profiling with Cytogentics and Routinely Acquired Serum Markers: SKY92 Combined with Revised ISS

Rowan Kuiper, PhD, Mark van Duin, PhD, Martin H Van Vliet, Erik H Van Beers, PhD, Berna Berna Beverloo, PhD, Sonja Zweegman, MD PhD, Tom Cupedo, PhD, Annemiek Broijl, MD PhD, Pieter Sonneveld, MD PhD

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-139987

Published: 2020

Journal Articles

Differential Effect of Upfront Intensification Treatment in Genetically Defined Myeloma Risk Groups - a Combined Analysis of ISS, Del17p and SKY92 Scores in the EMN-02/HOVON-95 MM Trial

Davine Hofste op Bruinink, MD MSc, Mark van Duin, PhD, Meral Beksac, MD, Christoph Driessen, MD, Heinz Ludwig, MD, Michael Vermeulen, BSc, Rowan Kuiper, MSc, Martin H van Vliet, PhD, Bronno van der Holt, PhD, Roman Hajek, MD PhD, Hans Erik Johnsen, MD Professor, Meletios A Dimopoulos, MD, Antonio Palumbo, MD, Michele Cavo, MD, Pieter Sonneveld, MD PhD

Blood (2018) 132 (Supplement 1): 3186.

https://doi.org/10.1182/blood-2018-99-119873

Published: 2018

Journal Articles

Transcriptomics in Multiple Myeloma Demonstrates an Association between Survival and Expression of T Cell Co-Signaling Ligands in Bone Marrow Derived Myeloma Plasma Cells

Pim Mutsaers, MD, Rowan Kuiper, MSc, Dora Hammerl, Msc, Mark van Duin, PhD, Bronno Van Der Holt, PhD, Sonja Zweegman, MDPhD, Walter M Gregory, Jan J Cornelissen, MD PhD, Annemiek Broyl, MD PhD, Reno Debets, PhD, Pieter Sonneveld, MDPhD

Blood (2018) 132 (Supplement 1): 241.

https://doi.org/10.1182/blood-2018-99-118488

Published: 2018

Journal Articles

Mmprofiler with SKY92 Combined with ISS Identifies High and Low Risk Multiple Myeloma in the VTD Arm of Gimema-MMY-3006

Erik H Van Beers, Carolina Terragna, Marina Martello, Elena Zamagni, MD, Michele Cavo, MD, Martin H van Vliet, PhD, Giovanni Martinelli, MD, Rowan Kuiper, MSc

Blood (2017) 130 (Supplement 1): 4358.

https://doi.org/10.1182/blood.V130.Suppl_1.4358.4358

Published: 2017

Journal Articles

The Level of Circulating Myeloma Cells at Diagnosis Correlates with a Plasma Cell Leukemia-like Phenotype of the Corresponding Myeloma Cells in Bone Marrow

Davine Hofste Op Bruinink, MD, Vincent van der Velden, PhD, Mark van Duin, PhD, Berna Beverloo, PhD, Jeroen te Marvelde, BSc, Chelsea den Hollander, BSc, Rowan Kuiper, MSc, Michel Delforge, MDPhD, Martin H van Vliet, PhD, Niels WCJ van de Donk, MDPhD, Hervé Avet-Loiseau, MDPhD, Philippe Moreau, MDPhD, Pieter Sonneveld, MDPhD

Blood (2017) 130 (Supplement 1): 4368.

https://doi.org/10.1182/blood.V130.Suppl_1.4368.4368

Published: 2017

Journal Articles

Validation of the EMC92/SKY92 Signature in HOVON-87/Nmsg-18: Gene Expression Based Prognostication Is Applicable in Elderly Patients with Newly Diagnosed Multiple Myeloma

Mark van Duin, PhD, Rowan Kuiper, BSc, Martin van Vliet, PhD, Annemiek Broijl, MD PhD, Leonie de Best, MSc, Erik van Beers, PhD, Bronno Van Der Holt, PhD, Heleen Visser-Wisselaar, PhD, Lizanne Bosman, BSc, Belinda Dumee, BSc, Fanni van den Bosch, BSc, Michael Vermeulen, BSc, Jasper Koenders, BSc, Marian Stevens-Kroef, PhD, Anders Waage, MD PhD, Sonja Zweegman, MD PhD, Pieter Sonneveld, MD PhD

Blood (2015) 126 (23): 2967.

https://doi.org/10.1182/blood.V126.23.2967.2967

Published: 2015

Journal Articles

Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System

Rowan Kuiper, Mark van Duin, Martin H. van Vliet, Annemiek Broijl, Bronno van der Holt, Laila el Jarari, Erik H. van Beers, George Mulligan, Hervé Avet-Loiseau, Walter M. Gregory, Gareth Morgan, Hartmut Goldschmidt, Henk M. Lokhorst, Pieter Sonneveld

Blood (2015) 126 (17): 1996–2004.

https://doi.org/10.1182/blood-2015-05-644039

Published: 2015

Includes: Supplemental data

Journal Articles

Single Sample Application of the EMC92/SKY92 Signature Using the Mmprofiler

Martin H. Van Vliet, PhD, Rowan Kuiper, BSc, Belinda Dumee, BSc, Leonie de Best, MSc, Peter J. van der Spek, PhD, Emmanuel M.E.H. Lesaffre, PhD, Mark van Duin, PhD, Anders Waage, MD PhD, Sonja Zweegman, MDPhD, Pieter Sonneveld, MDPhD, Erik H. van Beers, PhD

Blood (2014) 124 (21): 2026.

https://doi.org/10.1182/blood.V124.21.2026.2026

Published: 2014

Journal Articles

A Genome Wide Association Study Reveals Genetic Predisposition for Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma By Variation in the PREP1-Cbs Locus

Florence Magrangeas, Rowan Kuiper, BSc, Hervé Avet-loiseau, MD PhD, Wilfried Gouraud, Catherine Guérin, Henri Der Sakissian, Jérôme Suhard, Michel Attal, Pieter Sonneveld, MDPhD, Charles Dumontet, MD PhD, Philippe Moreau, Mark van Duin, PhD, Loic Campion, MD, Stephane Minvielle

Blood (2014) 124 (21): 2057.

https://doi.org/10.1182/blood.V124.21.2057.2057

Published: 2014

Journal Articles

Prediction of High and Low-Risk Multiple Myeloma Based on the EMC92 Gene Expression Signature and the International Staging System

Rowan Kuiper, BSc, Martin H. Van Vliet, PhD, Erik H. van Beers, PhD, Annemiek Broijl, MDPhD, George Mulligan, PhD, Hervé Avet-Loiseau, Walter Gregory, PhD, Gareth J. Morgan, MD PhD, Hartmut Goldschmidt, MD, Henk Lokhorst, MDPhD, Mark van Duin, PhD, Pieter Sonneveld, MDPhD

Blood (2014) 124 (21): 3358.

https://doi.org/10.1182/blood.V124.21.3358.3358

Published: 2014

Journal Articles

Comparison Of Conventional, FISH and GEP Prognostic Factors In Multiple Myeloma: Introducing a Novel Risk Stratification

Rowan Kuiper, Martin van Vliet, Annemiek Broyl, Yvonne de Knegt, Bronno van der Holt, Laila el Jarari, George Mulligan, Walter Gregory, PhD, Gareth J Morgan, MD PhD, Hartmut Goldschmidt, MD, Uta Bertsch, MD, Henk Lokhorst, Mark van Duin, Erik van Beers, Pieter Sonneveld, MD, Ph.D

Blood (2013) 122 (21): 3092.

https://doi.org/10.1182/blood.V122.21.3092.3092

Published: 2013

Journal Articles

High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance

Annemiek Broyl, Rowan Kuiper, Mark van Duin, Bronno van der Holt, Laila el Jarari, Uta Bertsch, Sonja Zweegman, Arjan Buijs, Dirk Hose, Henk M. Lokhorst, Hartmut Goldschmidt, Pieter Sonneveld

Blood (2013) 121 (4): 624–627.

https://doi.org/10.1182/blood-2012-06-438101

Published: 2013

Includes: Supplemental data

Journal Articles

Relation Between Cereblon Expression and Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Thalidomide

Annemiek Broyl, MD, Rowan Kuiper, BSc, Mark van Duin, PhD, Bronno van der Holt, PhD, Laila el Jarari, MSc, Uta Bertsch, MD, Sonja Zweegman, MD, PhD, Arjan Buijs, PhD, Dirk Hose, MD, PhD, Henk Lokhorst, MD, PhD, Hartmut Goldschmidt, MD, PhD, Pieter Sonneveld, MD

Blood (2012) 120 (21): 3973.

https://doi.org/10.1182/blood.V120.21.3973.3973

Published: 2012

Journal Articles

A High-Risk Survival Classifier for Multiple Myeloma

Rowan Kuiper, BSc, Annemiek Broyl, MD, Yvonne de Knegt, BSc, Martin H. van Vliet, PhD, Erik H. van Beers, PhD, Bronno van der Holt, PhD, Laila el Jarari, MSc, George Mulligan, PhD, Gareth Morgan, MD, Walter M Gregory, PhD, Hartmut Goldschmidt, MD, Henk M. Lokhorst, MD, Mark van Duin, PhD, Pieter Sonneveld, MD, PhD

Blood (2011) 118 (21): 1800.

https://doi.org/10.1182/blood.V118.21.1800.1800

Published: 2011

Journal Articles

Prognostic Impact of Genetic Subgroups and Development of Gene Classifiers for Response, PFS and OS In Multiple Myeloma Patients Treated with Bortezomib or Conventional Agents In HOVON65/GMMG-HD4 Trial

Annemiek Broyl, MD, Rowan Kuiper, Martin H. van Vliet, PhD, Erik H. van Beers, PhD, Yvonne de Knegt, Bronno van der Holt, PhD, Laila el Jarari, Berna Beverloo, PhD, H. Lokhorst, Sonja Zweegman, George Mulligan, PhD, Hartmut Goldschmidt, Mark van Duin, PhD, Pieter Sonneveld

Blood (2010) 116 (21): 445.

https://doi.org/10.1182/blood.V116.21.445.445

Published: 2010

Journal Articles

MicroRNA Profiling In Multiple Myeloma

Sophie Corthals, Su Ming Sun, Rowan Kuiper, Yvonne de Knegt, Annemiek Broyl, MD, Bronno van der Holt, H. Berna Beverloo, PhD, Justine K Peeters, Mark van Duin, PhD, Henk M Lokhorst, Sonja Zweegman, Mojca Jongen-Lavrencic, MD, PhD, P. Sonneveld

Blood (2010) 116 (21): 302.

https://doi.org/10.1182/blood.V116.21.302.302

Published: 2010

NARROW

Prommis Trial Prospectively Demonstrates the Efficacy of SKY92 Risk Stratification in Newly Diagnosed Multiple Myeloma Patients

Unveiling the Discrepancy in Multiple Myeloma Risk Classification between Clinical Practice and SKY92 Test and the Impact on Survival

Combining Plasma Cell Leukemia-like Status with the Second Revision of the International Staging System Improves Risk Classification

High-Risk Multiple Myeloma Patients Are Missed without Gene Expression Profiling

The Prognostic Power of Gene Expression Profiling with Cytogentics and Routinely Acquired Serum Markers: SKY92 Combined with Revised ISS

Differential Effect of Upfront Intensification Treatment in Genetically Defined Myeloma Risk Groups - a Combined Analysis of ISS, Del17p and SKY92 Scores in the EMN-02/HOVON-95 MM Trial

Transcriptomics in Multiple Myeloma Demonstrates an Association between Survival and Expression of T Cell Co-Signaling Ligands in Bone Marrow Derived Myeloma Plasma Cells

Mmprofiler with SKY92 Combined with ISS Identifies High and Low Risk Multiple Myeloma in the VTD Arm of Gimema-MMY-3006

The Level of Circulating Myeloma Cells at Diagnosis Correlates with a Plasma Cell Leukemia-like Phenotype of the Corresponding Myeloma Cells in Bone Marrow

Validation of the EMC92/SKY92 Signature in HOVON-87/Nmsg-18: Gene Expression Based Prognostication Is Applicable in Elderly Patients with Newly Diagnosed Multiple Myeloma

Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System

Single Sample Application of the EMC92/SKY92 Signature Using the Mmprofiler

A Genome Wide Association Study Reveals Genetic Predisposition for Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma By Variation in the PREP1-Cbs Locus

Prediction of High and Low-Risk Multiple Myeloma Based on the EMC92 Gene Expression Signature and the International Staging System

Comparison Of Conventional, FISH and GEP Prognostic Factors In Multiple Myeloma: Introducing a Novel Risk Stratification

High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance

Relation Between Cereblon Expression and Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Thalidomide

A High-Risk Survival Classifier for Multiple Myeloma

Prognostic Impact of Genetic Subgroups and Development of Gene Classifiers for Response, PFS and OS In Multiple Myeloma Patients Treated with Bortezomib or Conventional Agents In HOVON65/GMMG-HD4 Trial

MicroRNA Profiling In Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only